Summary
Florbetapir F 18 has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Alzheimer's Disease and Other Dementias would be drug repurposing rather than first-in-human development. This does not mean it is approved for Alzheimer's Disease and Other Dementias. No registered clinical trial in this database tests Florbetapir F 18 specifically in Alzheimer's Disease and Other Dementias. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study. The literature layer holds 3 publications for this pair: 3 clinical trial publications. Publication years run from 2015 to 2025. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Alzheimer's Disease and Other Dementias ranks 705 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Progressive and irreversible by definition; MMSE decline 1.07-3.4 points/year untreated; no spontaneous remission.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 26.0 (trials 0.0, literature 6.0, tier 15, approved bonus 5.0) |
| Registered trials | 0 total: 0 recruiting, 0 active / not yet recruiting, 0 completed, 0 other |
| Linked publications | 3 (3 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
No registered trial links Florbetapir F 18 to Alzheimer's Disease and Other Dementias in the current OSMF trial extract.
Published literature
- Clinical trial publication TRAILBLAZER-ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's diseaseSalloway S, Pain A, Lee E et al. · Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025 · PMID 40390253
- Clinical trial publication A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adultsTaylor MK, Sullivan DK, Swerdlow RH et al. · The American journal of clinical nutrition · 2017 · PMID 29070566
- Clinical trial publication Physical Activity and Amyloid-β Brain Levels in Elderly Adults with Intact Cognition and Mild Cognitive Impairmentde Souto Barreto P, Andrieu S, Payoux P et al. · Journal of the American Geriatrics Society · 2015 · PMID 26200930
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Florbetapir F 18 approved for Alzheimer's Disease and Other Dementias?
Florbetapir F 18 has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Alzheimer's Disease and Other Dementias would be drug repurposing rather than first-in-human development. This does not mean it is approved for Alzheimer's Disease and Other Dementias. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Florbetapir F 18 in clinical trials for Alzheimer's Disease and Other Dementias?
No registered clinical trial in this database tests Florbetapir F 18 specifically in Alzheimer's Disease and Other Dementias. The evidence below comes from published literature only, so any clinical signal has not yet been tested prospectively against this condition in a registered study.
What does the evidence show for Florbetapir F 18 in Alzheimer's Disease and Other Dementias?
The record for Florbetapir F 18 in Alzheimer's Disease and Other Dementias rests on 3 publications without a registered trial. This is a lead for hypothesis generation, not evidence of efficacy. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.